International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 3 , ISSUE 2 ( May-August, 2012 ) > List of Articles


Effectiveness of HP-hMG vs r-FSH in Patients undergoing IVF/ICSI Cycles with Moderate Male Factor Infertility

Rutvij Jay Dalal

Citation Information : Dalal RJ. Effectiveness of HP-hMG vs r-FSH in Patients undergoing IVF/ICSI Cycles with Moderate Male Factor Infertility. Int J Infertil Fetal Med 2012; 3 (2):51-56.

DOI: 10.5005/jp-journals-10016-1041

License: CC BY-NC 4.0

Published Online: 01-04-2015

Copyright Statement:  Copyright © 2012; The Author(s).



The aim of this case-control study was to compare the efficacy of highly purified human menopausal gonadotropin (HPhMG) vs recombinant follicle stimulating hormone (r-FSH) treatments following GnRH agonist suppression in patients undergoing intracytoplasmic sperm injection (ICSI) with moderate male factor infertility in terms of oocyte and embryo quality and clinical pregnancy outcomes.

Materials and methods

A total of 240 infertile women were treated with HP-hMG group (n: 120 patients) or (r-FSH group, n: 120 patients) following GnRH agonist suppression (long regimen). Inclusion criteria for the study groups were infertility due to moderate oligoastheno-teratospermia with no associated female infertility factor, previous ART cycles <2, female patients aged 19 to 35 years with normal basal FSH, regular ovulatory cycles and BMI <30 kg/m2.


Treatment durations and gonadotropin doses were similar in both groups. Cycle cancellation rates, clinical pregnancy and miscarriage rates, total and metaphase II oocytes retrieved, fertilization rate, number of embryos transferred were all similar in both groups. The clinical pregnancy rates were 45.9% (n: 50/109) in the r-FSH group and 40.4% (n: 44/109) in the HP-hMG group.


HP-hMG is effective as r-FSH in terms of oocyte and embryo quality and clinical pregnancy outcomes in patients undergoing ICSI with moderate male factor infertility.

How to cite this article

Dalal RJ, Pai H, Palshetkar N. Effectiveness of HP-hMG vs r-FSH in Patients undergoing IVF/ICSI Cycles with Moderate Male Factor Infertility. Int J Infertility Fetal Med 2012;3(2):51-56.

PDF Share
  1. A short narrative review of the feasibility of adopting mild ovarian stimulation for IVF as the current standard of care. Arch Gynecol Obstet 2012 Aug;286(2):505-10.
  2. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev 2012;13;6:CD009577.
  3. Gonadotropin therapy: A 20th century relic. Fertil Steril 2012;97:813-18.
  4. History and challenges surrounding ovarian stimulation in the treatment of infertility. Fertil Steril 2012;97:795-801.
  5. Clinical evidence of an LH ceiling effect induced by administration of recombinant human LH during the late follicular phase of stimulation cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003;18: 314-22.
  6. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI. Acta Obstet Gynecol Scand 2010;89:1053-60.
  7. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: A multicenter, prospective, randomized controlled trial. Fertil Steril 2010;94: 2467-69.
  8. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: A prospective, randomized and controlled trial. Gynecol Endocrinol 2012;28:540-44.
  9. A prospective, randomized, controlled trial comparing HP-hMG with r-FSH in women undergoing ICSI: Ovarian response and clinical outcomes. Hum Reprod 2003;18: 1194-99.
  10. Efficacy and safety of highly purified metropin versus r-FSH in IVF, ICSI cycles: A randomized, comparative trial. Fertil Steril 2002;78:520-28.
  11. Clinical outcome following stimulation with HP-hMG or r-FSH in patient undergoing IVF: A randomized assessor blind controlled trial. Hum Reprod 2006;21:3217-27.
  12. Joan-Carles Arce for the MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod 2007;22:2404-13.
  13. For the firm group. Effectiveness of highly purified human menopausal gonadotropin vs recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril 2008;89:1685-93.
  14. Meta-analysis of recombinant versus urinary-derived FSH: An update. Hum Reprod 2003;18:305-13.
  15. Ovulation induction in the new millennium: Recombinant folliclestimulating hormone versus human menopausal gonadotropin. Gynecol Endocrinol 2005;20:161-69.
  16. Cochrane Database Syst Rev 2003;(1): CD003973.
  17. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: A meta-analysis. RBM Online 2008;16:81-88.
  18. WHO laboratory manual for the examination of human semen and semen-cervical mucus interaction, (5th ed). WHO Press, World Health Organization, 2010.
  19. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotropins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod 1996;11:1854-58.
  20. Stimulation of ovarian follicular maturation with pure follicle stimulating hormone in women with gonadotropin deficiency. J Clin Endocrinol Metab 1988;66:552-56.
  21. Results of ovarian induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril 1991;56:1048-53.
  22. Induction of follicular growth using recombinant human folliclestimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril 1993;59:738-42.
  23. J Clin Endocrinol Metab 1998;83: 1507-14.
  24. Similar ovulation rates, but different follicular development with highly purified metropin compared with r-FSH in WHO group ll anovulatory infertility: A randomized controlled study. Hum Reprod 2006;21:1798-804.
  25. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005; 83:309-15.
  26. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 2004;81:1401-04.
  27. The human cumulus-oocyte complex geneexpression profile. Hum Reprod 2006;21:1705-19.
  28. Withdrawn: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2011;16(2):CD003973.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.